Introduction
Chronic myelogenous leukemia (CML) is characterized by a reciprocal t(9;22) chromosomal translocation, known as the Philadelphia chromosome, that fuses the truncated Bcr gene to the truncated c-Abl. 1, 2 Bcr-Abl is also often found in adult acute lymphocytic leukemia (ALL). 3 The Bcr-Abl gene encodes for character chimeric p210 and p185 proteins. 4 These are constitutively active tyrosine kinases which may induce resistance to apoptotic cell death. [5] [6] [7] [8] [9] [10] [11] [12] A number of protein kinases, including Raf-1, Src, and ErbB, depend on association with the chaperone protein, heat-shock protein 90 (Hsp90), for proper function and stability. The benzoquinone ansamycin geldanamycin (GA) binds to Hsp90 and specifically inhibits this chaperone's function, resulting in degradation of HSP90-associated proteins. 13, 14 The chimeric BCR-ABL exists in a complex with Hsp90, and GA causes degradation of BCR-ABL after 3-5 h of treatment. 15 Since BcrAbl expression is associated with resistance to cytotoxic agents, we hypothesized that treatment of Bcr-Abl-expressing cells with GA would restore their sensitivity to chemotherapeutic agents. Indeed our results confirm this prediction. Importantly, while sensitizing Bcr-Abl-expressing cells, GA protected parental cells from cytotoxic effects of doxorubicin (DOX). 
Materials and methods

Cell lines and reagents
HL60 and Jurkat, human leukemia cell lines, were obtained from American Type Culture Collection (Manassas, VA, USA). HL60-Bcr-Abl, a Bcr-Abl stable transfected HL-60 cells, were described previously. 8, 16 Paclitaxel (Taxol), was Bristol-Myers (Princeton, NJ, USA) product. Adriamycin (doxorubicin) was obtained from Sigma (St Louis, MO, USA) and dissolved in DMSO as a 2 mg/ml stock solution. STI 571 was kindly provided by Novartis Pharma (East Hanover, NJ, USA). The proteasome inhibitor PS-341 was a kind gift from Dr Peter Elliott, Proscript, Inc. (Cambridge, MA, USA).
Immunoblot analysis
Cells were lysed and soluble proteins were harvested in TNES buffer (50 mm Tris HCl pH 7.5, 100 mm NaCl, 2 mm EDTA, 1 mm sodium orthovanadate, 1% (v/v) NP40) containing protease inhibitors (20 g/ml aprotinin, 20 g/ml leupeptin, 1 mm PMSF). Proteins were resolved with SDS-PAGE as previously described. 15, 17 Immunoblotting was performed using rabbit polyclonal anti-human PARP (Upstate Biotechnology, Lake Placid, NY, USA), for Bcr using monoclonal anti-human Bcr antibodies N 2 (Oncogene Science, Calbiochem, San Diego, CA, USA).
MTT assay
Fifteen thousand cells were plated in 0.1 ml in 96-well flat bottom plates and then exposed to tested agents (final volume 0.2 ml per well). At the indicated time, 20 l of 5 mg/ml MTT solution in PBS was added to each well for 4 h. After removal of the medium, 170 l of DMSO was added to each well to dissolve the formazan crystals. The absorbance at 540 nm was determined using a Biokinetics plate reader (Bio-Tek Instruments, Inc, Winooski, VT, USA). Triplicate wells were assayed for each condition and standard deviations were determined.
Number of dead and live cells
Cells were plated in 24-well plates in 1 ml of medium, or in 96-well plates in 0.2 ml, and were treated with drugs. After the indicated time, cells were counted in triplicate on a Coulter Z1 cell counter (Hialeah, FL, USA). In addition, cells were incubated with trypan blue and the numbers of blue (dead) cells and transparent (live) cells were counted in a hemocytometer. 
Cell cycle analysis
Cells were washed with PBS and resuspended in 75% ethanol in PBS and kept at 4°C for at least 30 min. Prior to analysis, cells were washed again with PBS and resuspended and incubated for 30 min in propidium iodide staining solution containing 0.05 mg/ml propidium iodide (Sigma), 1 mm EDTA, 0.1% Triton-X-100 and 1 mg/ml RNAse A in PBS. The suspension was then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan (Franklin Lakes, NJ, USA).
Nuclear fragmentation assay
Cells were incubated with drugs for the indicated time. Cells were washed with PBS, pelleted on to glass slides in a cytocentrifuge, fixed with 90% ethanol with 10% glacial acid and stained with DAPI as described previously. 18 Nuclei were visualized under UV microscopy.
Figure 2
Reversal of resistance/sensitivity ratios in HL60 and K562 cells by GA. Effects of increasing concentrations of GA on the cytotoxicity caused by 500 nm DOX in either K562 (closed triangles) or HL60 (open triangles) cells. MTT assay was performed after 3 days as described in Materials and methods. At GA = 0 nM axis X, the values represent the cytotoxicity of 500 ng/ml alone. Results were calculated as the percent of values obtained with untreated cells and represent mean ± s.d.
Results
Pharmacological depletion of Bcr-Abl and cytotoxicity
In agreement with previous report, 15 treatment of K562 cells with 30-810 nm GA completely depleted Bcr-Abl protein (Figure 1a) . Similarly, 30 nm of GA caused a near-maximal growth inhibition of K562 cells (Figure 1b) . Previous studies have shown that K562 leukemia cells expressing Bcr-Abl are resistant to numerous therapeutic agents including anti-CD95 mAb, high-dose AraC, etoposide, paclitaxel, actinomycin D, staurosporine, and proteasome inhibitors. 5, 8, 9, 16, 18, 19 In contrast, GA was more cytotoxic in K562 cells than in HL60 cells (Figure 1b) .
GA sensitized K562 cells but protected HL60 cells
K562 cells were much more resistant to doxorubicin (DOX) than were HL60 cells. (60% and 4% survival, respectively; see Figure 2 , X-axis: GA = 0). Addition of 10-100 nm GA decreased survival of DOX-treated K562 cells. If sensitization by GA was due to depletion of Bcr-Abl, this effect should not be observed in HL60 cells. In fact, GA did not sensitize HL60 cells (Figure 2) . Unexpectedly, GA rendered these cells more resistant to DOX. Sensitization of K562 coupled with desensitization of HL60 resulted in the reversal of their relative sensitivities to DOX in the presence of GA (Figure 2) .
When added alone as well as with either PTX or DOX, GA depleted p210
BCR-ABL in K562 cells (Figure 3a) . Also, PTX and DOX slightly downregulated Bcr-Abl. This downregulation of Bcr-Abl occurred before apoptosis, since PARP was still intact 16 h after the treatment (Figure 3a) . In HL60 cells, Bcr levels were not affected by GA (Figure 3b ). Consistent with previous reports, 20, 21 both DOX and PTX caused apoptosis in HL60 cells, as evidenced by PARP cleavage (Figure 3b) . Remarkably, GA partially abrogated DOX-and PTX-induced PARP cleavage (Figure 3b) . Furthermore, this inhibition of PARP cleavage was accompanied by higher survival of HL60 cells (Figure 3d ). In contrast, GA increased toxicity of PTX and DOX in K562 cells (Figure 3c ). Since the activity of PTX is cell cycle-dependent, we next investigated by flow cytometry the effects of combinations of GA and PTX (Figure 4) . Treatment with GA caused G1 and G2 arrest. As expected, PTX caused G2/M arrest. Combination of PTX with GA decreased G2/M due to an increase in sub-G1-peaks, consistent with apoptosis.
Comparison of HL60 and HL60-Bcr/ABL
To rule out the possibility that differences in cellular background other than the expression of Bcr-Abl might determine opposite responses of HL60 and K562 cells, we compared parental HL60 cells with HL60 cells stably transfected with Bcr-Abl (HL60-Bcr-Abl cells). HL60-Bcr-Abl cells are much more resistant to chemotherapy than parental cells. 8, 16 In contrast, HL60-Bcr-Abl cells were more sensitive to GA (10-100 nm) than parental HL60 cells ( Figure 5 ). We next investiLeukemia gated combinations of GA with either PS-341, an inhibitor of the proteasome, or DOX ( Figure 6 ). As expected, HL60-BcrAbl were more resistant to PS-341 than were the parental cells (Figure 6a ). It is noteworthy that PS-341 and GA antagonized one another in HL60-Bcr-Abl cells but not in parental cells, consistent with the notion that GA targets Bcr-Abl for proteasomal degradation. Finally, GA sensitized HL60-Bcr-Abl cells to DOX, but protected the parental cells against DOX-induced cytotoxicity (Figure 6b ). In the absence of GA, HL60 cells were sensitive to DOX, whereas HL60-Bcr-Abl were resistant to DOX (Figure 6b , axis X: GA = 0). In the presence of GA, HL60-Bcr-Abl cells were more sensitive to DOX than were parental cells (Figure 6b ). This result was confirmed by examining nuclear fragmentation, a morphological marker of apoptosis. DOX induced nuclear fragmentation in HL60, but not in HL60-Bcr-Abl cells (Figure 7) . GA prevented nuclear fragmentation caused by DOX in HL60 cells, but caused nuclear fragmentation in DOX-treated HL60-Bcr-Abl cells (Figure 7) . We conclude that opposite effects of GA in BcrAbl-expressing and non-expressing HL60 cells depend solely on Bcr-Abl.
The kinase inhibitor, STI 571, sensitizes Bcr-Abl cells but does not protect parental HL60 cells
Finally, we compared GA with STI 571, an inhibitor of kinases including Bcr-Abl and Abl. 22 Unlike GA, STI 571 did not
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Figure 4
Cell cycle analysis of GA-treated K562 cells. K562 cells were treated with either 90 nm GA, 100 nm PTX, or their combination (PTX + GA), or left untreated (control). After 24 h, flow cytometry was performed as described in Materials and methods.
deplete the Bcr-Abl protein (Figure 8a ). Both STI 571 and GA caused comparable PARP cleavage in HL60-Bcr-Abl cells. DOX did not induce caspase-3 activation (data not shown) or PARP cleavage in Bcr-Abl cells (Figure 8a ). Both GA and STI 571 significantly increased DOX-induced death of HL60-BcrAbl cells (Figure 8c) . Therefore, degradation of the Bcr-Abl protein by GA and inhibition of the Bcr-Abl kinase by STI 571 resulted in similar effects in Bcr-Abl-expressing cells: sensitization of these cells to DOX. The role of Bcr-Abl was confirmed by using parental HL60 cells (Figure 8b ). Since HL60 cells do not express Bcr-Abl, we measured Raf-1 as a surrogate end point of GA effects. As expected, GA (alone and in combination) depleted cells of Raf-1, whereas STI 571 did not (Figure 8b) . DOX induced PARP cleavage, whereas GA and STI 571 did not (Figure 8b ). Unlike GA, STI 571 did not abro- 
Discussion
Apoptosis in response to chemotherapy is often evaded by cancer cells. 23 The expression of the BCR-ABL chimeric protein prevents apoptosis caused by a variety of anticancer agents. 22 Geldanamycin (GA), is an inhibitor of the chaperone Hsp90, and it promotes depletion of Hsp90-associated proteins, including Bcr-Abl. 15 Here we show that GA downregulated Bcr-Abl in Ph 1 -positive K562 cells and in HL60 cells stably transfected with Bcr-Abl. In both cell lines, a depletion of the Bcr-Abl protein and a near-maximal toxicity were achieved at concentrations of GA as low as 30 nm. Furthermore, GA sensitized Bcr-Abl-expressing cells to doxorubicin (DOX) and, albeit to a lesser degree, to paclitaxel (PTX).
Inhibitors of the Abl kinase, including STI 571, induce apoptosis in Bcr-Abl-positive cells. 6, 10, 11, 22, [24] [25] [26] [27] In agreement with previous results, [28] [29] [30] we show that STI 571 induced apoptosis in Bcr-Abl-expressing cells and sensitized Bcr-Abl expressing cells to chemotherapeutic agents. Given that GA and STI 571 inhibit Bcr-Abl activities by different mechanisms, these data confirm that inhibition of Bcr-Abl is responsible for sensitization caused by either GA or STI 571.
STI 571 has been remarkably effective in preclinical and clinical trials. 31 However, development of resistance to STI 571 has been reported, [32] [33] [34] thus validating GA-induced Bcr- 
Figure 7
Effects of GA and DOX on nuclear fragmentation of parental and Bcr-Abl-expressing HL60 cells. HL60 and HL60-Bcr-Abl cells were incubated with 500 ng/ml DOX, 90 nm GA, or their combination (DOX + GA), or were left untreated. After 20 h, DAPI staining for nuclear fragmentation was performed as described in Materials and methods.
Abl depletion as an alternative therapeutic approach. Unexpectedly, and unlike STI-571, GA protected parental HL60 cells against DOX-induced apoptosis. Although seemingly paradoxical, this phenomenon is likely a result of GA's reported ability to induce a compensatory elevation in the synthesis of several heat shock proteins including Hsp70. 35 It is well known that high levels of Hsp70 can inhibit apoptosis. 36 Using GA in this setting recalls the similar strategy of selectively protecting wt p53-expressing cells against paclitaxelinduced apoptosis by pretreatment with low concentrations of DOX. 37 Thus, use of GA to simultaneously increase the drug tolerance of normal cells, while improving the sensitivity of Bcr-Abl-expressing tumor cells to chemotherapy, might Leukemia decrease drug-related side-effects, while increasing a therapeutic index. Further experiments using primary BCR-ABLnegative cells will be necessary to determine the generality of this observation. 
